Background: Responses in NSCLC to agents targeting the PD-1/PD-L1 axis are correlated with PD-L1 expression by immunohistochemistry (IHC), tumor mutational burden (TMB), interferon associated mRNA Expression Profile (GEP) and the absence of liver metastases. Pegilodecakin (AM0010) is a pegylated recombinant human interleukin-10 that stimulates activation, survival and clonal expansion of intra-tumoral, tumor antigen specific CD8þ T cells. Pegilodecakin also up-regulates IFNc and the expression of MHC, which enables tumor antigen presentation in neoplasias of low mutational burden and promotes immunosurveillance by expanding effector memory T cells (Mumm et al. 2010(Mumm et al. , 2011. Finally, pegilodecakin reduces tumor inflammatory processes such as angiogenesis and and metastatic dissemination (Oft 2017), the offtarget auto-immune side effects of immunotherapy and the inflammatory-related side effects of some chemotherapies. Methods: In a 353 patient phase 1/1b dose escalation and expansion study, 34 pretreated NSCLC subjects received pegilodecakin with pembrolizumab or nivolumab. Responses were assessed by irRC. PD-L1 was tested with the 22C3 IHC assay, TMB by whole exome sequencing and pre-treatment GEP by Nanostring.
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Results:
Conclusions: Pegilodecakin when added to anti-PD-1 therapy in advanced NSCLC patients was associated with response rates and durability of benefit greater than has been seen with anti-PD-1 alone. Responses were seen in settings in which anti-PD-1 therapy has demonstrated limited benefit, such as absent PD-L1 expression, low TMB and/or the presence of liver metastasis. These preliminary findings support further studies of pegilodecakin with anti-PD-1 therapies. Background: Late line, triple negative breast cancer (TNBC) is an unmet need. Pegilodecakin (AM0010) is a pegylated recombinant human interleukin-10 that stimulates activation, survival and clonal expansion of intra-tumoral, tumor antigen specific CD8þ T cells. Pegilodecakin also up-regulates IFNc and the expression of MHC, which enables tumor antigen presentation in neoplasias of low mutational burden and promotes immunosurveillance by expanding effector memory T cells (Mumm et al. 2010 (Mumm et al. , 2011 . Finally, pegilodecakin reduces tumor inflammatory processes such as angiogenesis and and metastatic dissemination (Oft 2017), the off-target auto-immune side effects of immunotherapy and the inflammatory-related side effects of some chemotherapies. TMB Low (tumor mutational burden low) <243 mut/exome; 10 E (evaluable -baseline tumor assessment þ >1 post-baseline assessments, and no major protocol deviations); ITT (intent to treat); 11 irAE -Immune-Related Adverse Events (e.g. pneumonitis, adrenal insufficiency, thyroiditis, hypothyroiditis, hypophysitis, mucositis/stomatis, colitis, hepatitis, cholangitis, polyarthritis, myasthenia gravis, optic neuritis); Data cut on 05.01.18; Median follow-up for pembrolizumab cohort 37.3 months (35.9-39.1 months); Median follow-up for nivolumab cohort 23.2 months (9.1-32.0 months) Methods: In a 353 patient phase 1/1b dose escalation and expansion study conducted in the US from 2013 to 2017, 18 heavily pretreated TNBC subjects received pegilodecakin alone (N ¼ 8) or in combination with platinum and taxane-based chemotherapy (N ¼ 8) or platinum and gemcitabine chemotherapy (N ¼ 10). Responses were assessed by irRC. Results: G3/4 TrAEs in monotherapy are anemia (38%), thrombocytopenia (38%) and fatigue (25%); and in the platinum/taxane combo: anemia (75%), neutropenia (75%), thrombocytopenia (75%), leukopenia (50%), and febrile neutropenia (25%); in carbo/ gem combo: thrombocytopenia (60%), fatigue (30%) and anemia (20%). Conclusions: Pegilodecakin in combination with platinum and taxane-based chemotherapy in advanced TNBC was associated with objective responses and durable clinical benefit as measured by disease control and overall survival. These preliminary findings support further studies of pegilodecakin in combination with standard of care chemotherapy in both later and earlier stages patients with TNBC. Clinical trial identification: NCT02009449. Legal entity responsible for the study: ARMO BioSciences. Background: Checkpoint inhibition as monotherapy has limited success in advanced metastatic epithelial ovarian cancer (epOC) and strategies to increase immunogenicity are needed. Pegilodecakin (AM0010) is a pegylated recombinant human interleukin-10 that stimulates activation, survival and clonal expansion of intra-tumoral, tumor antigen specific CD8þ T cells. Pegilodecakin also up-regulates IFNc and expression of MHC, which enables tumor antigen presentation in neoplasias of low mutational burden (eg, epOC) and promotes immunosurveillance by expanding effector memory T cells (Mumm et al 2010 (Mumm et al , 2011 . Pegilodecakin reduces tumor inflammatory processes such as angiogenesis and metastatic dissemination (Oft 2017), the off-target autoimmune side effects of immunotherapy and the inflammatory-related side effects of some chemotherapies. Preclinical data suggest synergy of pegilodecakin in reducing tumor volume when combined with platinum/taxane based chemotherapy. Methods: In a 353 pt phase 1/1b dose escalation and expansion study conducted in the US (2013) (2014) (2015) (2016) (2017) , 12 platinum-refractory, heavily pretreated epOC pts received daily pegilodecakin alone (N ¼ 9) or in combination with platinum/taxane-based chemotherapy (N ¼ 3). Responses were assessed by irRC. Results: In monotherapy 4 (44%) had a PFS of more than 3.5 months and a survival of more than 14.7 months. No IRAEs were seen. G3/4 TrAEs in monotherapy: anemia (33%), fatigue (33%), thrombocytopenia (22%); in platinum/taxane combo: anemia (33%), diarrhea (33%), neutropenia (33%), thrombocytopenia (33%). 
